Skip to content

Study · Non-randomized trial · 2008

4 results

[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].

Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2008Cited by 3 (Europe PMC)

PMID18577961 (opens in a new tab)PepBankPUB-18577961
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialMechanism

    In patients with generalized anxiety disorder and neurasthenia, changes in the serum Th1/Th2 cytokine balance were found after 14 days of selank.

    In plain wordsIn patients with anxiety disorder and neurasthenia, immune signal balance in the blood changed after 14 days of selank.

    Peptide
    Selank
    Outcome
    Direction not reportedTh1/Th2 cytokine balance in serum
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 14 daysAs given in this study (human).

    Source sentences

    Summary
    The changes of the Th1/Th2 cytokine balance in vivo were found in the serum of patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days.
  2. 02LabEx vivo tissueMechanism

    In peripheral blood cells from patients with depression, selank at 10-7 M completely suppressed IL-6 gene expression.

    In plain wordsIn lab tests on blood cells from a depression group, selank completely suppressed the IL-6 gene activity.

    Peptide
    Selank
    Outcome
    DecreaseIL-6 gene expression in blood of patients with depression
    Study

    humann: not reported in source

    Peripheral blood cell culture
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10-7 MAs given in this study (human).

    Source sentences

    Summary
    The experiments in vitro revealed that the drug in concentration 10-7 M completely suppressed gene expression by peripheral blood IL-6 of patients with depression but not of the healthy controls.
  3. 03LabEx vivo tissueMechanism

    In peripheral blood cells from healthy controls, selank at 10-7 M did not suppress IL-6 gene expression.

    In plain wordsIn lab tests on blood cells from a healthy control group, selank did not suppress the IL-6 gene activity.

    Peptide
    Selank
    Outcome
    No significant changeIL-6 gene expression in blood of healthy controls
    Study

    humann: not reported in source

    Peripheral blood cell culture
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10-7 MAs given in this study (human).

    Source sentences

    Summary
    The experiments in vitro revealed that the drug in concentration 10-7 M completely suppressed gene expression by peripheral blood IL-6 of patients with depression but not of the healthy controls.
  4. 04LabEx vivo tissueMechanism

    In peripheral blood cell cultures from patients, IL-6 concentration increased significantly in the presence of selank.

    In plain wordsIn lab tests on blood cells from a patient group, the IL-6 protein level rose when selank was present.

    Peptide
    Selank
    Outcome
    IncreaseIL-6 concentration in culture of patient blood
    Study

    humann: not reported in source

    Peripheral blood cell culture
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At the same time, the significant increase (p<0,05) of IL-6 concentration was observed in the cell culture of peripheral blood of patients in the presence of selank.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.